JP5675758B2 - 安定な結晶性5−メチルテトラヒドロ葉酸塩 - Google Patents
安定な結晶性5−メチルテトラヒドロ葉酸塩 Download PDFInfo
- Publication number
- JP5675758B2 JP5675758B2 JP2012264084A JP2012264084A JP5675758B2 JP 5675758 B2 JP5675758 B2 JP 5675758B2 JP 2012264084 A JP2012264084 A JP 2012264084A JP 2012264084 A JP2012264084 A JP 2012264084A JP 5675758 B2 JP5675758 B2 JP 5675758B2
- Authority
- JP
- Japan
- Prior art keywords
- type
- methyl
- crystalline
- water
- methyltetrahydrofolate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 title description 26
- 235000007635 levomefolic acid Nutrition 0.000 title description 21
- 239000011578 levomefolic acid Substances 0.000 title description 21
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 claims description 14
- ZNOVTXRBGFNYRX-OLZOCXBDSA-N (2s)-2-[[4-[[(6r)-2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid Chemical compound C([C@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-OLZOCXBDSA-N 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- JMNIIIQOMSQWJN-ZEXVLMPOSA-L calcium;(2s)-2-[[4-[[(6s)-2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical compound [Ca+2].C([C@@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1.C([C@@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1 JMNIIIQOMSQWJN-ZEXVLMPOSA-L 0.000 description 11
- 238000002425 crystallisation Methods 0.000 description 9
- 230000008025 crystallization Effects 0.000 description 9
- 239000000725 suspension Substances 0.000 description 8
- 239000013078 crystal Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229940105150 5-methyltetrahydrofolic acid Drugs 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000005169 Debye-Scherrer Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- JMNIIIQOMSQWJN-NVGTXZLJSA-L calcium (2S)-2-[[4-[[(6R)-2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical compound [Ca+2].C([C@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1.C([C@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1 JMNIIIQOMSQWJN-NVGTXZLJSA-L 0.000 description 4
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- -1 alkaline earth metal salts Chemical class 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000004052 folic acid antagonist Substances 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005460 tetrahydrofolate Substances 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical class N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-NEPJUHHUSA-N 6R-Tetrahydrofolic acid Chemical compound C([C@@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-NEPJUHHUSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- JMNIIIQOMSQWJN-ACGFUFEJSA-L calcium;(4s)-4-[[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical compound [Ca+2].C1NC=2N=C(N)NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1.C1NC=2N=C(N)NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1 JMNIIIQOMSQWJN-ACGFUFEJSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000010193 neural tube defect Diseases 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000035581 susceptibility to neural tube defects Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
例中に記載される5−メチルテトラヒドロ葉酸塩の含有量は、それぞれHPLCによって測定され、そして%−表面で記載される。水分含有量はカールフィシャー法で測定される。
結晶性5−メチルテトラヒドロ葉酸塩の安定性測定のために、この物質を比較試料と一緒に25℃及び相対湿度60%で大気下に保存する。周期的間隔で5−メチルテトラヒドロ葉酸塩の残存含有量を測定し、出発値と比較して記載する。
結晶性5−メチルテトラヒドロ葉酸塩の構造性質(結晶度)を調べるために、これらの物質による粉末X線図(回折スペクトル)を採用する。
5−メチル−(6S)−テトラヒドロ葉酸の結晶性カルシウム塩(タイプI)
回折メーター:透過
モノクロメーター:Curved Ge(111)
波長:1.54098 Cu
検出器:ライナーPSD
スキャンモード:Debye−Scherrer/Moving PSD/Fixed omega
2θスキャン
!ピークサーチパラメーター:期待半値幅 : .150
! 有意水準 : 2.5
! ピーク高さ水準:10
ピークリスト〔範囲1:2θ=5.000 34.980 .020 Imax=765〕
5−メチル−(6S)−テトラヒドロ葉酸の結晶性カルシウム塩(タイプII)
回折メーター:透過
モノクロメーター:Curved Ge(111)
波長:1.54098 Cu
検出器:ライナーPSD
スキャンモード:Debye−Scherrer/Moving PSD/Fixed omega
2θスキャン
!ピークサーチパラメーター:期待半値幅 : .150
! 有意水準 : 2.5
! ピーク高さ水準:10
ピークリスト〔範囲1:2θ=5.000 34.980 .020 Imax=526〕
5−メチル−(6S)−テトラヒドロ葉酸の結晶性カルシウム塩(タイプIII)
回折メーター:透過
モノクロメーター:Curved Ge(111)
波長:1.540598 Cu
検出器:ライナーPSD
スキャンモード:Debye−Scherrer/Moving PSD/Fixed omega
2θスキャン
!ピークサーチパラメーター:期待半値幅 : .150
! 有意水準 : 2.5
! ピーク高さ水準:10
ピークリスト〔範囲1:2θ=5.000 34.980 .020 Imax=817〕
5−メチル−(6S)−テトラヒドロ葉酸の結晶性カルシウム塩(タイプIV)
回折メーター:透過
モノクロメーター:Curved Ge(111)
波長:1.540598 Cu
検出器:ライナーPSD
スキャンモード:Debye−Scherrer/Moving PSD/Fixed omega
2θスキャン
!ピークサーチパラメーター:期待半値幅 : .150
! 有意水準 : 2.5
! ピーク高さ水準:10
ピークリスト〔範囲1:2θ=5.000 34.980 .020 Imax=473〕
タイプ 選択された2θ値
タイプI 6.5、13.3、16.8及び20.1
タイプII 5.3、 6.9、18.7及び21.1
タイプIII 6.8、10.2、15.4及び22.5
タイプIV 6.6、15.9、20.2及び22.5
結晶性5−メチル−(6S)−テトラヒドロ葉酸カルシウム塩の溶解度を次の表に記載する。
タイプ 20℃での溶解度
0.9%NaCl 水
タイプI 1.6% 1.1%
タイプII 5.8% 3.8%
タイプIII 1.5% 1.0%
N2の導入下に室温で水75mlに5−メチル−(6S)−テトラヒドロ葉酸7.5gを添加して、30%水酸化ナトリウム溶液でpH12に調整する。得られた澄明な溶液を37%塩酸でpH7.5に調整し、これに水11.7ml中に塩化カルシウム6H2O7.15gを含有する溶液を加える。得られた白色懸濁液を5時間攪拌して室温で吸引濾取し、水で十分に洗滌して、45℃で減圧乾燥する。
5−メチル−(6R,S)−テトラヒドロ葉酸70gを水780ml中に入れ、30%NaOH45.2gでpH7.5に調整する。澄明な淡い赤色溶液を水140ml中に塩化カルシウム6H2O62.7gを含有する溶液を加え、濾過して、少量の水で十分に洗滌する。得られた粗精製物を水中に懸濁させて、90℃で湿室中で24時間処理する。
5−メチル−(6R)−テトラヒドロ葉酸16.5gを92℃の水100ml及び塩化カルシウム6H2O50g中に入れる。澄明な淡い黄色懸濁液を10分間、91℃で攪拌し、濾過し、少量の水で十分に洗滌して、35℃で減圧乾燥する。
水130kgを予め入れ、ついで5−メチル−(6S)−テトラヒドロ葉酸12.8kgを添加する。30%NaOH約9.1kgでpH−値11.6に調整し、ついで37%塩酸約1.9kgで7.6に調整する。澄明な溶液に炭0.3kg及びセルフロック(cellflock)0.3kgを含有する懸濁液を添加し、濾過して、水13Lで十分に洗滌する。濾液に塩化カルシウム・2H2O8.3kgを含有する溶液を添加し、90℃に加熱して、30分間攪拌する。生成物を熱い状態で濾過して、水2×20kgで十分に洗滌する。得られた湿性粗生成物を水115L中に懸濁させ、90℃に加熱して、直ちに熱いうちに濾過し、水2×20kgで十分に洗滌して、40℃で減圧乾燥させる。
水1600mlを予め入れ、ついで5−メチル−(6S)−テトラヒドロ葉酸194kgを添加する。30%NaOH約80mlでpH−値7.0に調整する。澄明な溶液に、水190ml中に炭20kg及びセルフロック20gを含有する懸濁液を添加し、濾過して、水で十分に洗滌する。濾液に5.5M塩化カルシウム溶液950mlを添加し、90℃に加熱して、60分間攪拌する。生成物を熱い状態で濾過して、水で十分に洗滌し、ついで45℃で減圧乾燥させる。
水554gを予め入れ、ついで5−メチル−(6S)−テトラヒドロ葉酸53.1kgを添加する。30%NaOHでpH値を7.5に調整する。澄明な溶液に炭1.3g、セルフロック1.3g及び水19.5gを添加する。懸濁液を濾過して、水55mlで十分に洗滌する。濾液に水84.6g中に塩化カルシウム・6H2O52.0gを含有する溶液を添加し、90℃に加熱して、結晶性5−メチルテトラヒドロ葉カルシウム塩100mgを結晶種として入れる。結晶化させた後に、生成物を90℃の熱い状態で濾過して、水2×103gで十分に洗滌する。得られた湿性粗生成物を90℃で水480ml中に懸濁させ、90℃に加熱して、直ちに熱いうちに濾過し、上述のように十分に洗滌して、45℃で減圧乾燥させる。
5−メチル−(6S)−テトラヒドロ葉酸カルシウム塩15.8gを水140ml中でN2の導入下に95℃に加熱して、95℃で30分後、白色懸濁液を熱い状態で吸引濾取し、水で十分に洗滌して、35℃で減圧乾燥する。
5−メチル−(6S)−テトラヒドロ葉酸カルシウム塩20.0gを水180ml中でN2の導入下に100℃に加熱して、100℃で30分後、白色懸濁液を熱い状態で吸引濾取し、水で十分に洗滌して、25℃で減圧乾燥する。
Claims (1)
- 5−メチル−(6S)−テトラヒドロ葉酸の結晶性カルシウム塩であって、該結晶性塩が2θ値5.3、6.9、18.7及び21.1(タイプII)を示す、上記結晶性カルシウム塩。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH00695/99A CH693905A5 (de) | 1999-04-15 | 1999-04-15 | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
CH19990695/99 | 1999-04-15 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000112606A Division JP5202774B2 (ja) | 1999-04-15 | 2000-04-13 | 安定な結晶性5−メチルテトラヒドロ葉酸塩 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013047278A JP2013047278A (ja) | 2013-03-07 |
JP5675758B2 true JP5675758B2 (ja) | 2015-02-25 |
Family
ID=4193016
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000112606A Expired - Lifetime JP5202774B2 (ja) | 1999-04-15 | 2000-04-13 | 安定な結晶性5−メチルテトラヒドロ葉酸塩 |
JP2012264084A Expired - Lifetime JP5675758B2 (ja) | 1999-04-15 | 2012-12-03 | 安定な結晶性5−メチルテトラヒドロ葉酸塩 |
JP2012264086A Expired - Lifetime JP5675760B2 (ja) | 1999-04-15 | 2012-12-03 | 安定な結晶性5−メチルテトラヒドロ葉酸塩 |
JP2012264085A Expired - Lifetime JP5675759B2 (ja) | 1999-04-15 | 2012-12-03 | 安定な結晶性5−メチルテトラヒドロ葉酸塩 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000112606A Expired - Lifetime JP5202774B2 (ja) | 1999-04-15 | 2000-04-13 | 安定な結晶性5−メチルテトラヒドロ葉酸塩 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012264086A Expired - Lifetime JP5675760B2 (ja) | 1999-04-15 | 2012-12-03 | 安定な結晶性5−メチルテトラヒドロ葉酸塩 |
JP2012264085A Expired - Lifetime JP5675759B2 (ja) | 1999-04-15 | 2012-12-03 | 安定な結晶性5−メチルテトラヒドロ葉酸塩 |
Country Status (19)
Country | Link |
---|---|
US (1) | US6441168B1 (ja) |
EP (5) | EP2192120B1 (ja) |
JP (4) | JP5202774B2 (ja) |
KR (2) | KR100774012B1 (ja) |
CN (1) | CN1154648C (ja) |
AT (2) | ATE451372T1 (ja) |
AU (1) | AU782641B2 (ja) |
CA (1) | CA2305926C (ja) |
CH (1) | CH693905A5 (ja) |
CY (2) | CY1109874T1 (ja) |
DE (2) | DE50015815D1 (ja) |
DK (4) | DK2189459T3 (ja) |
ES (3) | ES2336190T3 (ja) |
HU (1) | HU229423B1 (ja) |
NO (1) | NO325495B1 (ja) |
PT (4) | PT2192120E (ja) |
RU (1) | RU2265605C2 (ja) |
TW (1) | TWI285205B (ja) |
ZA (1) | ZA200001851B (ja) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH693905A5 (de) * | 1999-04-15 | 2004-04-15 | Eprova Ag | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
WO2002083151A2 (en) * | 2000-12-14 | 2002-10-24 | Tufts University | Compositions and methods for treating an arthritic condition |
MXPA06005451A (es) | 2003-11-17 | 2007-01-26 | Biomarin Pharm Inc | Metodos y composiciones para el tratamiento de trastornos metabolicos. |
DE602005026352D1 (de) * | 2004-09-15 | 2011-03-31 | Nipro Corp | Wässrige, stabile (6S)-Folinsäurelösung zur Injektion |
JP2008523090A (ja) * | 2004-12-08 | 2008-07-03 | バイオマリン ファーマシューティカル インコーポレイテッド | 新生児肺高血圧症の治療のための方法および組成物 |
UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
KR20090029824A (ko) * | 2006-07-06 | 2009-03-23 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 피임용 및 선천성 기형 위험 예방용 제약 제제 |
US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
CN101489563A (zh) * | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
EP1891959A1 (de) * | 2006-08-14 | 2008-02-27 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen |
CH698729B1 (de) | 2007-05-30 | 2009-10-15 | Cerbios Pharma Sa | Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure. |
EP2027855A1 (de) | 2007-08-24 | 2009-02-25 | Bayer Schering Pharma AG | Verwendung von Gestagenen in Kombination mit (6S)5-Methyltetrahydrofolat zur Therapie der Endometriose mit gleichzeitiger Verminderung von Therapie-Nebenwirkungen sowie der Verminderung des Risikos angeborener Fehlbildungen bei Eintritt einer Gravidität |
US20090060997A1 (en) * | 2007-08-27 | 2009-03-05 | Christian Seitz | Process for producing a pharmaceutical preparation for therapeutic treatment of endometriosis containing a combination of a gestagen and (6s)-5-methyltetrahydrofolate |
BRPI0908231A2 (pt) * | 2008-02-13 | 2015-07-21 | Bayer Schering Pharma Akltiengesellschaft | Sistema de liberação de fármaco com efeito estabilizante |
AU2009214193A1 (en) * | 2008-02-13 | 2009-08-20 | Bayer Intellectual Property Gmbh | Estradiol-containing drug delivery system |
DK2245032T3 (da) * | 2008-02-20 | 2015-06-22 | Gnosis Spa | Folater, sammensætninger og anvendelser deraf |
SG10201404000RA (en) | 2009-07-10 | 2014-10-30 | Linzy O Scott Iii | Methods and compositions for treating thyroid-related medical conditions with reduced folates |
UY32836A (es) | 2009-08-12 | 2011-03-31 | Bayer Schering Pharma Ag | Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato |
EP2575825A4 (en) | 2010-02-12 | 2014-01-01 | Alexander Vuckovic M D Llc | COMPOSITIONS AND METHODS FOR TREATING DEPRESSION |
JP5785622B2 (ja) * | 2010-12-03 | 2015-09-30 | コチャク ファルマ イラチュ ヴェキミャ サン.アー.シェーKocak Farma Ilac Ve Kimya San.A.S | その構造内にグルタミン酸部分を有する葉酸拮抗薬の新規な製造方法 |
CN102516247A (zh) * | 2010-12-15 | 2012-06-27 | 连云港金康医药科技有限公司 | A型l-5-甲基四氢叶酸钙盐多晶型及其制备方法 |
EP2502625A1 (en) | 2011-03-21 | 2012-09-26 | GMT Fine Chemicals SA | Process for the preparation of crystalline levofolinic acid |
CN102584826B (zh) * | 2012-01-20 | 2015-04-29 | 连云港金康医药科技有限公司 | (6s)-5-甲基四氢叶酸盐晶型及其制备方法 |
CN102775407B (zh) * | 2012-01-20 | 2015-08-05 | 连云港金康医药科技有限公司 | 稳定的无定型5-甲基四氢叶酸盐及其制备方法 |
WO2013107236A1 (zh) * | 2012-01-20 | 2013-07-25 | 连云港金康和信药业有限公司 | (6s)-5-甲基四氢叶酸盐晶型及其制备方法 |
CN102702200B (zh) * | 2012-04-25 | 2014-11-12 | 连云港金康和信药业有限公司 | (6rs)-5-甲基四氢叶酸钙盐晶型及其制备方法 |
WO2013163917A1 (zh) * | 2012-04-13 | 2013-11-07 | 连云港金康和信药业有限公司 | 化合物jk12a及其制备 |
CN103450202B (zh) * | 2012-06-04 | 2015-07-01 | 南京莱因医药科技有限公司 | L-5-甲基四氢叶酸与有机碱加成盐的方法 |
CN103664945B (zh) * | 2012-09-07 | 2016-01-20 | 南京莱因医药科技有限公司 | L-5-甲基四氢叶酸氨基酸盐的制备方法 |
CN103694239B (zh) * | 2012-09-27 | 2016-12-21 | 上海科胜药物研发有限公司 | 一种5‑甲基‑(6s)‑四氢叶酸晶型a及其制备方法 |
EP2781214A1 (en) * | 2013-03-22 | 2014-09-24 | Chemo Research, S.L. | Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca) |
EP3027178A2 (en) * | 2013-07-29 | 2016-06-08 | Adare Pharmaceuticals, Inc. | Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture |
US20160053281A1 (en) | 2013-08-15 | 2016-02-25 | The University Court Of The University Of Edinburgh | Enhanced Expression Of RNA Vectors |
US9492421B1 (en) | 2013-11-14 | 2016-11-15 | Argent Development Group, Llc | Nutritional supplements for treatment of iron deficiency anemia |
US9629846B1 (en) | 2013-11-14 | 2017-04-25 | Argent Development Group, Llc | Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women |
EP2878600B1 (en) * | 2013-12-02 | 2018-06-27 | Cerbios-Pharma S.A. | Stable complexes of an alkaline earth metal salt of N5-methyl-tetrahydrofolic acid and a polyol |
CN103980279B (zh) * | 2014-04-16 | 2016-07-06 | 悦康药业集团有限公司 | 一种甲氨蝶呤化合物及注射用甲氨蝶呤 |
WO2015193778A1 (en) | 2014-06-16 | 2015-12-23 | Mylan Laboratories Ltd. | Crystalline form of levomefolate calcium |
CN107812195B (zh) * | 2014-09-04 | 2021-04-20 | 连云港金康和信药业有限公司 | (6s)‐5‐甲基‐四氢叶酸钙盐的稳定药物组合物 |
EP3190112A4 (en) * | 2014-09-04 | 2017-09-13 | Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. | Composition of (6s)-5-methyl tetrahydrofolic acid or salt thereof as well as preparation therefor and application thereof |
CN104225609B (zh) | 2014-09-20 | 2018-05-18 | 中国药科大学 | 一种炎症靶向的中性粒细胞递药系统及其应用 |
WO2016135707A1 (en) | 2015-02-27 | 2016-09-01 | Nestec S.A. | Diagnosis of major depressive disorder, mild cognitive impairment, and alzheimer's disease and other neurologic and psychiatric disorders |
WO2016185413A1 (en) | 2015-05-20 | 2016-11-24 | Nestec S.A. | Modified release formulations |
CN107698591A (zh) * | 2015-09-25 | 2018-02-16 | 上海华理生物医药有限公司 | (6s)-5-甲基四氢叶酸锌盐晶型及其制备方法 |
DE202015105351U1 (de) | 2015-10-09 | 2016-01-07 | Apotheke am Schlossplatz Inh. Mario Ganster e.K. | Diätetische Zusammensetzung |
KR101712807B1 (ko) | 2015-10-19 | 2017-03-07 | 오인숙 | 스테인레스 빔 제조장치 |
CN105237539A (zh) * | 2015-10-29 | 2016-01-13 | 上海应用技术学院 | A晶型(6s)-5-甲基四氢叶酸锌盐及其制备方法 |
CN107304212A (zh) * | 2016-04-21 | 2017-10-31 | 常州爱诺新睿医药技术有限公司 | 一种无定型l-5-甲基四氢叶酸氨基酸盐及其制备方法 |
AU2017397463B2 (en) | 2016-11-03 | 2022-01-06 | HedoniaUSA, Inc. | Compositions and methods for treating depression |
FI3609894T3 (fi) * | 2017-03-31 | 2024-10-23 | Merck Patent Gmbh | 5-metyyli-(6S)-tetrahydrofoolihapon kiteinen natriumsuola |
CN110461844B (zh) * | 2017-03-31 | 2024-03-12 | 默克专利股份有限公司 | 5-甲基-(6s)-四氢叶酸与有机碱的结晶二元钠盐 |
WO2018178144A1 (en) | 2017-03-31 | 2018-10-04 | Merck Patent Gmbh | Crystalline sodium salt of 5-methyl-(6s)-tetrahydrofolic acid |
EP3461826A1 (en) | 2017-09-29 | 2019-04-03 | Aprofol AG | Multifunctional folate salts |
ES2966936T3 (es) * | 2018-07-06 | 2024-04-25 | Merck Patent Gmbh | Sal cristalina que comprende ácido 5-metil-(6S)-tetrahidrofólico y 4-(2-hidroxietil)-morfolina |
JP7395556B2 (ja) * | 2018-07-06 | 2023-12-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 5-メチル-(6s)-テトラヒドロ葉酸及びアミノ酸エチルエステルの結晶塩 |
FI3817812T3 (fi) * | 2018-07-06 | 2023-12-12 | Merck Patent Gmbh | 5-metyyli-(6S)-tetrahydrofoolihapon ja L-isoleusiinietyyliesterin kiteinen suola |
US11992491B2 (en) | 2018-07-06 | 2024-05-28 | Merck Patent Gmbh | Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester |
CN112312968A (zh) * | 2018-07-06 | 2021-02-02 | 默克专利股份有限公司 | 5-甲基-(6s)-四氢叶酸和l-亮氨酸乙酯的结晶盐 |
EP3646873A1 (en) * | 2018-10-31 | 2020-05-06 | Aprofol AG | Folate salts |
EP3666260A1 (en) | 2018-12-13 | 2020-06-17 | Laboratorios Leon Farma SA | Ethinyl estradiol-beta-cyclodextrin complex and process for preparing thereof |
US20230162351A1 (en) | 2020-04-23 | 2023-05-25 | National University Corporation Shiga University Of Medical Science | Diagnosis assistance device, machine learning device, diagnosis assistance method, machine learning method, machine learning program, and alzheimers prediction program |
WO2021228788A1 (en) | 2020-05-15 | 2021-11-18 | Alfasigma S.P.A. | Composition comprising methylfolate |
EP4501315A1 (en) | 2023-08-04 | 2025-02-05 | Lesaffre et Compagnie | Liquid formulations of folates |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1572137A (en) * | 1977-02-22 | 1980-07-23 | Bioresearch Sas Del Dr Livio C | Stable compositions for therapeutic use based on d,1-5-methyltetrahydrofolic acid and its salts |
US5223500A (en) * | 1977-02-22 | 1993-06-29 | Bioresearch S.P.A. | Stable pharmaceutical composition of alkaline or alkaline earth 5-methyl tetrahydrofolate |
DE3821875C1 (ja) * | 1988-06-29 | 1990-02-15 | Eprova Ag, Forschungsinstitut, Schaffhausen, Ch | |
CH680731A5 (ja) | 1990-04-12 | 1992-10-30 | Sapec Fine Chemicals | |
CH681303A5 (ja) | 1991-01-16 | 1993-02-26 | Eprova Ag | |
CH684270A5 (de) | 1991-10-04 | 1994-08-15 | Sapec Fine Chemicals | Verfahren zur Herstellung von Erdalkalimetallsalzen von (6R)-N(10)-Formyl-5,6,7,8-tetrahydrofolsäure. |
CH683261A5 (it) * | 1991-10-10 | 1994-02-15 | Applied Pharma Res | Procedimento per la preparazione dell'acido metiltetraidrofolico nella forma (6(R,S)(-))N-5 e separazione del diastereoisomero attivo (6(S)(-))N-5) sotto forma di sali. |
CH682664A5 (en) | 1991-10-15 | 1993-10-29 | Eprova Ag | Stable salts of 5,10-methylene tetrahydrofolate. |
CH682665A5 (de) * | 1991-10-29 | 1993-10-29 | Sapec Fine Chemicals | Verfahren zur Reinigung von rohen Erdalkalimetallsalzen von N(5)-Methyl-5,6,7,8-tetrahydrofolsäure. |
DE4136921A1 (de) * | 1991-11-11 | 1993-05-13 | Knoll Ag | Verfahren zur trennung von 5-methyl-tetrahydrofolsaeure |
CH686672A5 (de) * | 1992-12-01 | 1996-05-31 | Cerbios Pharma Sa | Verfahren zur Herstellung von (6S)-5,6,7,8-Tetrahydrofolsaeure. |
CH686369A5 (de) * | 1994-05-09 | 1996-03-15 | Eprova Ag | Stabile kristalline (6S)- und (6R)-Tetrahydrofolseure. |
CH689831A5 (de) * | 1995-11-07 | 1999-12-15 | Eprova Ag | Stabile kristalline Tetrahydrofolsaeure-Salze. |
CA2243981C (en) | 1996-01-31 | 2005-09-06 | South Alabama Medical Science Foundation | Food and vitamin preparations containing the natural isomer of reduced folates |
CH693905A5 (de) * | 1999-04-15 | 2004-04-15 | Eprova Ag | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
-
1999
- 1999-04-15 CH CH00695/99A patent/CH693905A5/de not_active IP Right Cessation
-
2000
- 2000-04-08 DK DK09178426.4T patent/DK2189459T3/da active
- 2000-04-08 PT PT09178428T patent/PT2192120E/pt unknown
- 2000-04-08 ES ES00107623T patent/ES2336190T3/es not_active Expired - Lifetime
- 2000-04-08 ES ES09178427T patent/ES2374369T3/es not_active Expired - Lifetime
- 2000-04-08 DE DE50015815T patent/DE50015815D1/de not_active Expired - Lifetime
- 2000-04-08 EP EP09178428A patent/EP2192120B1/de not_active Expired - Lifetime
- 2000-04-08 DK DK09178427.2T patent/DK2194057T3/da active
- 2000-04-08 PT PT09178427T patent/PT2194057E/pt unknown
- 2000-04-08 DK DK09178428.0T patent/DK2192120T3/da active
- 2000-04-08 DK DK00107623.1T patent/DK1044975T3/da active
- 2000-04-08 AT AT00107623T patent/ATE451372T1/de active
- 2000-04-08 PT PT00107623T patent/PT1044975E/pt unknown
- 2000-04-08 EP EP06010738A patent/EP1695975A1/de not_active Withdrawn
- 2000-04-08 AT AT09178426T patent/ATE496052T1/de active
- 2000-04-08 EP EP00107623A patent/EP1044975B1/de not_active Expired - Lifetime
- 2000-04-08 PT PT09178426T patent/PT2189459E/pt unknown
- 2000-04-08 EP EP09178426A patent/EP2189459B1/de not_active Expired - Lifetime
- 2000-04-08 DE DE50016064T patent/DE50016064D1/de not_active Expired - Lifetime
- 2000-04-08 ES ES09178428T patent/ES2374371T3/es not_active Expired - Lifetime
- 2000-04-08 EP EP09178427A patent/EP2194057B1/de not_active Expired - Lifetime
- 2000-04-12 NO NO20001886A patent/NO325495B1/no not_active IP Right Cessation
- 2000-04-12 TW TW089106827A patent/TWI285205B/zh not_active IP Right Cessation
- 2000-04-12 AU AU27689/00A patent/AU782641B2/en not_active Expired
- 2000-04-12 ZA ZA200001851A patent/ZA200001851B/xx unknown
- 2000-04-13 JP JP2000112606A patent/JP5202774B2/ja not_active Expired - Lifetime
- 2000-04-13 CA CA002305926A patent/CA2305926C/en not_active Expired - Lifetime
- 2000-04-14 RU RU2000109346/04A patent/RU2265605C2/ru active
- 2000-04-14 CN CNB00108884XA patent/CN1154648C/zh not_active Expired - Lifetime
- 2000-04-14 KR KR1020000019508A patent/KR100774012B1/ko not_active IP Right Cessation
- 2000-04-14 HU HU0001560A patent/HU229423B1/hu unknown
- 2000-04-17 US US09/551,405 patent/US6441168B1/en not_active Expired - Lifetime
-
2007
- 2007-05-30 KR KR1020070052657A patent/KR100874368B1/ko active IP Right Grant
-
2010
- 2010-03-04 CY CY20101100212T patent/CY1109874T1/el unknown
-
2011
- 2011-03-03 CY CY20111100250T patent/CY1111313T1/el unknown
-
2012
- 2012-12-03 JP JP2012264084A patent/JP5675758B2/ja not_active Expired - Lifetime
- 2012-12-03 JP JP2012264086A patent/JP5675760B2/ja not_active Expired - Lifetime
- 2012-12-03 JP JP2012264085A patent/JP5675759B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5675758B2 (ja) | 安定な結晶性5−メチルテトラヒドロ葉酸塩 | |
JP4898081B2 (ja) | 安定な結晶性(6s)−テトラヒドロ葉酸 | |
KR100702201B1 (ko) | 안정한결정질테트라하이드로엽산염 | |
JPH05294968A (ja) | 5,10−メチレンテトラヒドロ葉酸の安定な塩 | |
US11377448B2 (en) | Crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid | |
JP2020512383A (ja) | 5−メチル−(6s)−テトラヒドロ葉酸の結晶性ナトリウム塩 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121204 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121204 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20140303 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140311 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20140328 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140610 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140616 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140909 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141126 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141224 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5675758 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |